Pivotal role of microRNA-33 in metabolic syndrome: A systematic review

ARYA Atherosclerosis

Volumn 9, Issue 6, 2013, Pages 372-376

  Gharipour, Mojgan ^a   Sadeghi, Masoumeh ^b  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Insulin Resistance Syndrome X; MicroRNA 33; Regulatory Role

Indexed keywords

BIOLOGICAL MARKER; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN; MICRORNA; MICRORNA 33; STEROL REGULATORY ELEMENT BINDING PROTEIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; TUMOR MARKER; UNCLASSIFIED DRUG;

CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DIETARY INTAKE; FATTY ACID OXIDATION; HOMEOSTASIS; HUMAN; INFLAMMATION; INSULIN RELEASE; LIFESTYLE MODIFICATION; LIPID METABOLISM; METABOLIC DISORDER; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; NONHUMAN; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW;

EID: 84891327265     PISSN: 17353955     EISSN: 22516638     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Gharipour M, Kelishadi R, Khosravi A, Shirani S, Masjedi M, Sarrafzadegan N. The impact of a community trial on the pharmacological treatment in the individuals with the metabolic syndrome: findings from the Isfahan Healthy Heart Program, 2001-2007. Arch Med Sci 2012; 8(6): 1009-17.
2. Gharipour M, Sarrafzadegan N, Sadeghi M, Andalib E, Talaie M, Shafie D, et al. Predictors of metabolic syndrome in the Iranian population: waist circumference, body mass index, or waist to hip ratio? Cholesterol 2013; 2013: 198384.
3. Sarrafzadegan N, Gharipour M, Sadeghi M, Khosravi AR, Tavassoli AA. Metabolic syndrome in Iranian elderly. ARYA Atheroscler 2012; 7(4): 157-61.
4. Talaei M, Sadeghi M, Marshall T, Thomas GN, Kabiri P, Hoseini S, et al. Impact of metabolic syndrome on ischemic heart disease-a prospective cohort study in an Iranian adult population: Isfahan Cohort Study. Nutr Metab Cardiovasc Dis 2012; 22(5): 434-41.
5. Sarrafzadegan N, Kelishadi R, Baghaei A, Hussein SG, Malekafzali H, Mohammadifard N, et al. Metabolic syndrome: an emerging public health problem in Iranian women: Isfahan Healthy Heart Program. Int J Cardiol 2008; 131(1): 90-6.
6. Gharipour M, Kelishadi R, Toghianifar N, Tavassoli AA, Khosravi AR, Sajadi F, et al. Socioeconomic disparities and smoking habits in metabolic syndrome: evidence from isfahan healthy heart program. Iran Red Crescent Med J 2011; 13(8): 537-43.
7. Sarrafzadegan N, Gharipour M, Ramezani MA, Rabiei K, Zolfaghar B, Tavassoli AA, et al. Metabolic syndrome and health-related quality of life in Iranian population. J Res Med Sci 2011; 16(3): 254-61.
8. Mousavi E, Gharipour M, Tavassoli A, Sadri GH, Sarrafzadegan N. Multiparity and risk of metabolic syndrome: Isfahan Healthy Heart Program. Metab Syndr Relat Disord 2009; 7(6): 519-24.
9. Kelishadi R, Gharipour M, Sadri GH, Tavasoli AA, Amani A. Cardiovascular disease risk factors, metabolic syndrome and obesity in an Iranian population. East Mediterr Health J 2008; 14(5): 1070-9.
10. Gharipour M, Kelishadi R, Sarrafzadegan N, Baghaei A, Yazdani M, Anaraki J, et al. The association of smoking with components of the metabolic syndrome in non-diabetic patients. Ann Acad Med Singapore 2008; 37(11): 919-23.
11. Sidorenkov O, Nilssen O, Brenn T, Martiushov S, Arkhipovsky VL, Grjibovski AM. Prevalence of the metabolic syndrome and its components in Northwest Russia: the Arkhangelsk study. BMC Public Health 2010; 10: 23.
12. Al-Rasadi K, Sulaiman K, Panduranga P, Al-Zakwani I. Prevalence, characteristics, and inhospital outcomes of metabolic syndrome among acute coronary syndrome patients from Oman. Angiology 2011; 62(5): 381-9.
13. Kumbasar B, Yenigun M, Ataoglu HE, Sar F, Serez K, Turker T, et al. The prevalence of metabolic syndrome in different ethnic groups in Turkey. J Int Med Res 2013; 41(1): 188-99.
14. Hosseinpanah F, Borzooei S, Barzin M, Farshadi M, Sarvghadi F, Azizi F. Diagnostic values of metabolic syndrome definitions for detection of insulin resistance: Tehran Lipid and Glucose Study (TLGS). Arch Iran Med 2012; 15(10): 606-10.
15. Prasad H, Ryan DA, Celzo MF, Stapleton D. Metabolic syndrome: definition and therapeutic implications. Postgrad Med 2012; 124(1): 21-30.
16. Tregouet DA, Konig IR, Erdmann J, Munteanu A, Braund PS, Hall AS, et al. Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease. Nat Genet 2009; 41(3): 283-5.
17. Vattikuti S, Guo J, Chow CC. Heritability and genetic correlations explained by common SNPs for metabolic syndrome traits. PLoS Genet 2012; 8(3): e1002637.
18. Wu C, Gong Y, Yuan J, Gong H, Zou Y, Ge J. Identification of shared genetic susceptibility locus for coronary artery disease, type 2 diabetes and obesity: a meta-analysis of genome-wide studies. Cardiovasc Diabetol 2012; 11: 68.
19. Sarkozy M, Zvara A, Gyemant N, Fekete V, Kocsis GF, Pipis J, et al. Metabolic syndrome influences cardiac gene expression pattern at the transcript level in male ZDF rats. Cardiovasc Diabetol 2013; 12: 16.
20. Samani NJ, Erdmann J, Hall AS, Hengstenberg C, Mangino M, Mayer B, et al. Genomewide association analysis of coronary artery disease. N Engl J Med 2007; 357(5): 443-53.
21. Povel CM, Boer JM, Onland-Moret NC, Dolle ME, Feskens EJ, van der Schouw YT. Single nucleotide polymorphisms (SNPs) involved in insulin resistance, weight regulation, lipid metabolism and inflammation in relation to metabolic syndrome: an epidemiological study. Cardiovasc Diabetol 2012; 11: 133.
22. Guo X, Cui J, Jones MR, Haritunians T, Xiang AH, Chen YD, et al. Insulin clearance: confirmation as a highly heritable trait, and genome-wide linkage analysis. Diabetologia 2012; 55(8): 2183-92.
23. Erdmann J, Willenborg C, Nahrstaedt J, Preuss M, Konig IR, Baumert J, et al. Genome-wide association study identifies a new locus for coronary artery disease on chromosome 10p11.23. Eur Heart J 2011; 32(2): 158-68.
24. Schunkert H, Konig IR, Kathiresan S, Reilly MP, Assimes TL, Holm H, et al. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet 2011; 43(4): 333-8.
25. Davies RW, Wells GA, Stewart AF, Erdmann J, Shah SH, Ferguson JF, et al. A genome-wide association study for coronary artery disease identifies a novel susceptibility locus in the major histocompatibility complex. Circ Cardiovasc Genet 2012; 5(2): 217-25.
26. Ramirez CM, Goedeke L, Fernandez-Hernando C. "Micromanaging" metabolic syndrome. Cell Cycle 2011; 10(19): 3249-52.
27. Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Kerin MJ. MicroRNAs as Novel Biomarkers for Breast Cancer. J Oncol 2009; 2009: 950201.
28. Musso G, Gambino R, Cassader M. Emerging molecular targets for the treatment of nonalcoholic fatty liver disease. Annu Rev Med 2010; 61: 375-92.
29. Najafi-Shoushtari SH. MicroRNAs in cardiometabolic disease. Curr Atheroscler Rep 2011; 13(3): 202-7.
30. Moore KJ, Rayner KJ, Suarez Y, Fernandez-Hernando C. The role of microRNAs in cholesterol efflux and hepatic lipid metabolism. Annu Rev Nutr 2011; 31: 49-63.
31. Fernandez-Hernando C, Moore KJ. MicroRNA modulation of cholesterol homeostasis. Arterioscler Thromb Vasc Biol 2011; 31(11): 2378-82.
32. Gerin I, Clerbaux LA, Haumont O, Lanthier N, Das AK, Burant CF, et al. Expression of miR-33 from an SREBP2 intron inhibits cholesterol export and fatty acid oxidation. J Biol Chem 2010; 285(44): 33652-61.
33. Najafi-Shoushtari SH, Kristo F, Li Y, Shioda T, Cohen DE, Gerszten RE, et al. MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis. Science 2010; 328(5985): 1566-9.
34. Rayner KJ, Suarez Y, Davalos A, Parathath S, Fitzgerald ML, Tamehiro N, et al. MiR-33 contributes to the regulation of cholesterol homeostasis. Science 2010; 328(5985): 1570-3.
35. Fernandez-Hernando C, Ramirez CM, Goedeke L, Suarez Y. MicroRNAs in metabolic disease. Arterioscler Thromb Vasc Biol 2013; 33(2): 178-85.
36. Fernandez-Hernando C, Suarez Y, Rayner KJ, Moore KJ. MicroRNAs in lipid metabolism. Curr Opin Lipidol 2011; 22(2): 86-92.
37. Horie T, Ono K, Horiguchi M, Nishi H, Nakamura T, Nagao K, et al. MicroRNA-33 encoded by an intron of sterol regulatory element-binding protein 2 (Srebp2) regulates HDL in vivo. Proc Natl Acad Sci U S A 2010; 107(40): 17321-6.
38. Ono K, Kuwabara Y, Han J. MicroRNAs and cardiovascular diseases. FEBS J 2011; 278(10): 1619-33.
39. Rayner KJ, Sheedy FJ, Esau CC, Hussain FN, Temel RE, Parathath S, et al. Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. J Clin Invest 2011; 121(7): 2921-31.